Close Menu

Scipher Medicine: Jerry Conway

Jun 12, 2020

Scipher Medicine has named Jerry Conway as senior vice president of market access. He will focus on patient access to Scipher's precision diagnostic tools beginning with PrismRA, a molecular signature test that predicts non-response to anti-TNFs for patients with rheumatoid arthritis, and is slated to launch later this year. Conway most recently served as executive vice president at CDx Diagnostics.

More Like This

Apr 13, 2021

Macrogen Europe: Bongcho Kim

Sequencing services provider Macrogen Europe has appointed Bongcho Kim as CEO. He has been tasked with expanding the company's sequencing and bioinformatics capabilities.

Kim was previously director of technology and innovation of Seoul-based Macrogen. He joined the firm in 2013 as general manager for next-generations sequencing overseas sales before being promoted to director and VP.

Kim holds a doctorate in pathology from Seoul National University.

Apr 12, 2021

ACMG: Susan Klugman, Shweta Dhar, Hutton Kearney, David Stevenson, Jerry Vockley

The American College of Medical Genetics and Genomics has added five new members to its board of directors, including its new president-elect. They will serve six-year terms starting this month.

Susan Klugman is ACMG's president-elect. She is the director of the division of reproductive and medical genetics at Albert Einstein College of Medicine and Montefiore Medical Center. Klugman holds an a bachelor of science in biometry and statistics from Cornell University and an MD from New York University School of Medicine. She is board-certified in clinical genetics and in obstetrics and gynecology.

Shweta Dhar is an associate professor in the department of molecular & human genetics and the department of internal medicine at Baylor College of Medicine. She is a graduate of Nathiba Hargovandas Lakhmichand Municipal Medical College in India and holds an MS in biotechnology from Stephen F. Austin State University in Texas. She is board-certified in clinical genetics and internal medicine.

Hutton Kearney is vice chair of hereditary genomics in the Mayo Clinic Division of Laboratory Genetics and Genomics and an assistant professor of laboratory medicine and pathology. She holds a BS in secondary education from Auburn University and a PhD in genetics and molecular biology from the University of North Carolina at Chapel Hill. She is board-certified in clinical cytogenetics and clinical molecular genetics.

David Stevenson is a professor of pediatrics in the division of medical genetics at Stanford University. He holds a BA in biology from Utah State University and an MD from the University of Utah.

Jerry Vockley is chief of the division of medical genetics and director of the Center for Rare Disease Therapy at UPMC Children's Hospital of Pittsburgh. He holds an undergraduate degree from Carnegie Mellon University as well as an MD and a PhD in genetics from the University of Pennsylvania School of Medicine. He is board-certified in clinical genetics and in clinical biochemical/molecular genetics.

Apr 12, 2021

Castle Biosciences: Kristen Oelschlager

Castle Biosciences has appointed Kristen Oelschlager as chief operating officer. Oelschlager had been serving as the company's chief operations officer since August 2020. Prior to that, she served as senior vice president of clinical operations from January 2018 to August 2020, VP of clinical operations from 2013 to 2018, and executive director of operations from October 2008 to 2013.
Oelschlager also served as director of clinical research for Arizona Pulmonary Specialists from May 1996 to September 2008.
Apr 12, 2021

Genetic Technologies: Michael Tonroe

Michael Tonroe has been appointed as CFO of Australian molecular diagnostics company Genetic Technologies, effective June 28. Previously, he was CFO and company secretary at Opthea, and before that, CFO and company secretary at the Australian Synchrotron. Tonroe holds a graduate degree in business studies from Buckingham University in the UK.

Apr 09, 2021

Micronoma: Jennifer Wargo

Micronoma, a company using signals from the tumor-related microbiome for liquid biopsy-based cancer diagnosis, has appointed Jennifer Wargo to its scientific advisory board. Wargo is a professor of surgical oncology and genomic medicine at the University of Texas MD Anderson Cancer Center.

Apr 08, 2021

Mission Bio: Yan Zhang, Charlie Silver

Single-cell analysis firm Mission Bio has appointed Yan Zhang as CEO.

Zhang joins Mission Bio after 10 years at Thermo Fisher Scientific, where she led that firm's commercial organization in China for genetic sciences and clinical next-generation sequencing and was general manager for its reproductive health and microarray businesses. Prior to Thermo, Zhang held product management and commercialization roles at Affymetrix, NuGen Technologies, and Molecular Devices. She holds a PhD in biochemistry from the Medical College of Wisconsin.

Former CEO Charlie Silver, a Mission Bio cofounder, will move into an advisory role.

Apr 06, 2021

Nautilus Biotechnology: Matt Murphy

Nautilus Biotechnology has appointed Matt Murphy as general counsel.

Murphy brings more than 25 years of experience as senior legal counsel for life sciences companies. He was previously VP and general counsel for both 10x Genomics and Pacific Biosciences and has advised companies including Caliper Technologies, BioElectron Technology, and Nanosys.

Murphy holds a law degree from the University of San Francisco.

Apr 06, 2021

NRGene: Keith Blanks, Richard Calk

NRGene has hired Keith Blanks as chief commercial officer and Richard Calk as chief strategy officer. Blanks previously was senior VP of sales and marketing at Calyxt, where he led the launch of one of the world's first gene-edited food products. Calk joins NRGene after serving as president and COO of Neogen. NRGene said that the two will help the Israeli company grow in North America.

Apr 05, 2021

Quadrant Biosciences: Brady Millican

Quadrant Biosciences announced Brady Millican has joined the firm as executive VP of sales. He has more than 30 years of experience in sales, marketing, business development, and operations in the medical diagnostics and prognostics space and was most recently chief business officer of Admera Health. Before that, he had senior level sales and marketing positions at Bostwick, Ameripath, and Dianon Laboratories. Based in Syracuse, New York, Quadrant has developed Clarifi ASD, a molecular saliva-based test for autism spectrum disorder, as well as Clarifi COVID-19, a saliva-based test codeveloped with the SUNY Upstate Medical University, which received Emergency Use Authorization from the US Food and Drug Administration in September.

Apr 05, 2021

Akoya Biosciences: Frederick Pla

Akoya Biosciences has appointed Frederic Pla as its chief operating officer. Pla most recently served as chief operating officer at the Parker Institute for Cancer Immunotherapy. Prior to this, Pla served as COO at Genomic Health before its acquisition by Exact Sciences in 2019. He has also served in leadership positions at Life Technologies, GE Healthcare, and NASA.

Apr 02, 2021

BioSkryb: Sean Keohane

BioSkryb has appointed Sean Keohane as senior vice president of commercial operations to spearhead commercialization of the company's ResolveDNA products for singe-cell whole-genome amplification. Keohane previously was VP of US marketing and sales at Numares. He has also previously held a variety of sales, marketing, and management positions at companies such as Molecular Devices, Thermo Fisher Scientific, Qiagen, Ciphergen Biosystems, Ventana Medical Systems, and Roche.

Apr 01, 2021

Applied DNA Sciences: Clay Shorrock

Clay Shorrock has been appointed as chief legal officer and executive director of business development at Applied DNA Sciences. He previously served as the company's in-house general and IP counsel from 2016 to 2019 and as outside general and IP counsel after that. Shorrock holds a JD with a concentration in IP from Seton Hall University Law School and a BA in biology from Franklin and Marshall College.

Mar 31, 2021

Tag.bio: Sanjay Padhi

Sanjay Padhi has joined Tag.bio as executive VP and chief technologist. He comes to the San Francisco-based data analytics startup from Amazon Web Services, where he was head of AWS research. Prior to that, he was a scientist at CERN. Padhi holds a PhD in high energy physics from McGill University.

Mar 31, 2021

Genome Medical: Brandon Poe, Marco Barcella, Russell Glass

South San Francisco-based digital health firm Genome Medical has made appointments to its management team and board of directors.

Brandon Poe has become the company's CFO. Previously, he was VP of finance at Illumina, and before that, CFO of medical device firm Sotera Wireless. He holds an MBA from the University of Chicago Booth School of Business and a bachelor's degree from Bucknell University.

Marco Barcella has been appointed as Genome Medical's chief product officer. Most recently, he held strategic product positions at Tiatros and at IBM Watson Health. He holds an MBA from the NYU Stern School of Business and a master of science degree from the University of Virginia.

Russell Glass has joined the firm as an independent director. He is the CEO of on-demand mental health company Ginger. Prior to that, he was the founder and CEO of Bizo, a B2B marketing and data firm that was sold to LinkedIn in 2014, which he then joined.

Mar 31, 2021

CareDx: Titte Srinivas, Steven Stone, Dustin Leach, Martyn Edney, More

CareDx has appointed Titte Srinivas as vice president of digital development and clinical integration, Steven Stone as VP of KidneyCare, Dustin Leach as VP of customer experience, and Martyn Edney as senior VP and head of human resources.

Srinivas is a transplant nephrologist who joins CareDx from University Hospitals in Cleveland, where he served as the chief of the division of nephrology and hypertension and Peter B. DeOreo Chair in Nephrology and Dialysis. Stone joins CareDx from from Myriad Genetics, where he served as VP of cancer genomics and developed products for personalized medicine in oncology. Leach joins CareDx from Teva Pharmaceuticals, where he most recently served as senior director of patient services – program development. Edney joins CareDx from Iqvia, where he served as VP of HR for the US and Canada.

The company also announced that it has promoted Marica Grskovic to VP of cell transplant therapy, and Jere Ramsey-Lester to VP of HR.

Grskovic joined CareDx nine years ago and has played a role in overseeing the design and development of the company's transplant diagnostic tests. Ramsey-Lester has been with CareDx since 2019, and has served as interim head of HR for the past year. She has held leadership positions in human resources at TreeHouse Foods, ConAgra Foods, and Fiserv.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.